Trial record 3 of 10 for: "Colorectal Adenoma" | "Cyclooxygenase Inhibitors"
Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib (UAB0040)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00582660|
Recruitment Status : Completed
First Posted : December 28, 2007
Results First Posted : August 7, 2014
Last Update Posted : June 15, 2017
University of Alabama at Birmingham
Information provided by (Responsible Party):
Marty Heslin, University of Alabama at Birmingham
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Triple (Participant, Care Provider, Investigator); Primary Purpose: Treatment|
The most prominent factor that limited enrollment was this period of time was at the point that the FDA released its finding about the possible cardiac risks associated with Rofecoxib (VIOXX).